Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ANIXBullishCorporate Developmentsnews

High materiality7/10

Anixa's lira-cel shows early stable disease signal in ovarian cancer trial

Oct 5, 2026, 8:32 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive early signal (stable disease at high dose) with no DLTs improves risk-reward; continued OS signals and data maturation could lift ANIX shares, though early-stage data limit valuation impact.

AI summary

What happened, with direct paths to the underlying reporting

Anixa reported a 90-day stable disease signal in its Phase 1 lira-cel ovarian cancer trial at the highest dose, with no dose-limiting toxicities observed. Several patients have survived beyond one year, including one over two years, hinting at durability and evolving efficacy as data accrues at Moffitt.

Fifth dose cohort patient showed stable disease at 90 days.
No dose-limiting toxicities observed across all patients.
Multiple patients survived beyond one year; one over two years.
High-dose cohort (1x10^7 CAR+ cells/kg) shows early signals.
Trial site Moffitt Center underscores trial credibility and enrollment pace.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.